Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab
Clinical Oral Investigations · 2022-03 · 26 (3) · 2839-2852
DOI: 10.1007/s00784-021-04261-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Oral Investigations, online erschienen am 23.11.2021. Verfasst von Alexander Wick und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery and Facial Plastic Surgery, University Hospital, LMU Munich, Lindwurmstr. 2a, 80336, Munich, Germany. Al…. Hauptthemen laut MEDLINE: Bisphosphonate-Associated Osteonecrosis of the Jaw, Bone Density Conservation Agents, Denosumab. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ludwig-Maximilians-Universität München.
Abstract (Originalsprache)
Objectives
While risk factors of bisphosphonate (BP) associated osteonecrosis of the jaw have been properly analyzed, studies focusing on risk factors associated with denosumab (DNO) are sparse. The purpose of this study was to identify risk factors influencing the onset of medication-related osteonecrosis of the jaw (MRONJ) in patients receiving antiresorptive treatment (ART) with DNO by comparing patients suffering from MRONJ and patients without MRONJ. Multiple variables were evaluated including the impact of a previous BP intake. Materials and methods A retrospective single-center cohort study with patients receiving DNO was conducted. One-hundred twenty-eight patients were included and divided into three groups: I (control, n = 40) receiving DNO with absence of MRONJ; group II (Test 1, n = 46), receiving DNO with presence of MRONJ; and group III (Test 2, n = 42) sequentially receiving BP and DNO with presence of MRONJ. Patients’ medical history, focusing on the identification of MRONJ risk factors, was collected and evaluated. Parameters were sex, age, smoking habit, alcohol consumption, underlying disease (cancer type, osteoporosis), internal diseases, additional chemo/hormonal therapy, oral inflammation, and trauma.
Results
The following risk factors were identified to increase MRONJ onset significantly in patients treated with DNO: chemo/hormonal therapy ( p = 0.02), DNO dosage ( p < 0.01), breast cancer ( p = 0.03), intake of corticosteroids ( p = 0.04), hypertension ( p = 0.02), diabetes mellitus ( p = 0.04), periodontal disease ( p = 0.03), apical ostitis ( p = 0.02), and denture use ( p = 0.02). A medication switch did not affect MRONJ development ( p = 0.86).
Conclusions
Malignant diseases, additional chemotherapy, DNO dosage, and oral inflammations as well as diabetes mellitus and hypertension influence MRONJ onset in patients treated with DNO significantly. Clinical relevance Patients receiving ART with DNO featuring aforementioned risk factors have a higher risk of MRONJ onset. These patients need a sound and regular prophylaxis in order to prevent the onset of MRONJ under DNO treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery and Facial Plastic Surgery, University Hospital, LMU Munich, Lindwurmstr. 2a, 80336, Munich, Germany. Alex.wickhh@gmail.com.
- Department of Oral and Maxillofacial Surgery and Facial Plastic Surgery, University Hospital, LMU Munich, Lindwurmstr. 2a, 80336, Munich, Germany.
- Department of Oral and Maxillofacial Surgery, University of Halle, Ernst-Grube-Straße 40, 06120, Halle, Germany.
- Medizin & Aesthetik, Clinic for Oral and Maxillofacial and Plastic Surgery, Lenbachplatz 2a, 80333, Munich, Germany.
- Department of Oral and Maxillofacial Surgery, University of Aachen, Pauwelsstraße 30, 52074, Aachen, Germany.
- Department of Oral and Maxillofacial Surgery, University of Heidelberg, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Förderung
- Ludwig-Maximilians-Universität München
Zitieren
APA
Wick, A., Bankosegger, P., Otto, S., Hohlweg-Majert, B., Steiner, T., Probst, F., Ristow, O., & Pautke, C. (2022). Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab. Clinical Oral Investigations, 26(3), 2839-2852. https://doi.org/10.1007/s00784-021-04261-4
Vancouver
Wick A, Bankosegger P, Otto S, Hohlweg-Majert B, Steiner T, Probst F, et al. Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab. Clinical Oral Investigations. 2022;26(3):2839-2852. doi:10.1007/s00784-021-04261-4
BibTeX
@article{Wick2022,
author = {Wick, Alexander and Bankosegger, Philipp and Otto, Sven and Hohlweg-Majert, Bettina and Steiner, Timm and Probst, Florian and Ristow, Oliver and Pautke, Christoph},
title = {Risk factors associated with onset of medication-related osteonecrosis of the jaw in patients treated with denosumab},
journal = {Clinical Oral Investigations},
year = {2022},
volume = {26},
number = {3},
pages = {2839--2852},
doi = {10.1007/s00784-021-04261-4}
}
EUVIMED